Why Is Adenocard (Adenosine) So Hard to Find? [Explained for 2026]

If you work in an emergency department, cardiology office, or any clinical setting that relies on Adenocard (adenosine injection) to convert life-threatening heart rhythms, you already know how stressful it is when this drug is hard to find. Unlike most medications, adenosine cannot be substituted on a whim — it is the first-line agent recommended by the American Heart Association (AHA) for paroxysmal supraventricular tachycardia (PSVT). When it is unavailable, clinical teams must pivot quickly and not every facility has a backup plan.

This post explains the key reasons Adenocard can be difficult to source in 2026, what drives supply disruptions for injectable drugs like adenosine, and what clinical teams can do when their usual distributor runs low.

What Is Adenocard and Why Is It So Important?

Adenocard is the brand name for adenosine injection (3 mg/mL), a fast-acting antiarrhythmic used intravenously to stop PSVT — a rapid heart rate originating above the ventricles. It works by transiently blocking conduction through the AV node, interrupting the reentry circuit that drives the arrhythmia. Because it has an ultra-short half-life of under 10 seconds, the window to get it into systemic circulation is narrow, and the drug must be administered as a rapid IV bolus close to the heart.

The drug is also used under the brand name Adenoscan for pharmacologic stress testing in patients unable to exercise during nuclear myocardial perfusion imaging. Both uses require reliable, uninterrupted supply — which is exactly where the challenge lies.

Why Do Injectable Drugs Like Adenosine Experience Supply Problems?

Sterile injectable medications are among the most vulnerable drugs in the U.S. supply chain. According to research by IQVIA, sterile injectables account for a disproportionate share of all drug shortages — and as of mid-2024, the FDA reported over 100 active shortages, with more than half lasting longer than two years. Adenosine is not immune to this structural fragility. Here are the main reasons supply can tighten:

• Consolidated manufacturing: A small number of manufacturers produce most of the U.S. adenosine supply. When one facility faces a slowdown, the ripple effect is immediate.
• Demand spikes: Seasonal fluctuations in cardiac events and stress test scheduling can drive sudden increases in demand that outpace distribution capacity.
• Distributor allocation: Even when national supply is technically adequate, individual distributors may allocate inventory unevenly, leaving some hospitals or clinics without stock while others have surplus.
• Packaging and raw material delays: The specialized Ansyr prefilled syringe system used for Adenocard requires specific components that can face their own supply chain delays.

Has Adenosine Been in a Shortage Before?

Yes. Adenosine injection has experienced notable supply disruptions historically. The most significant period was during the broader injectable drug shortage crisis of 2011–2012, when hospitals across the U.S. faced simultaneous shortages of dozens of sterile injectables. Adenosine was among the drugs affected, creating real challenges for emergency departments and cardiology practices.

As of 2026, adenosine does not appear on the FDA's active shortage list. However, localized and intermittent availability issues continue to occur at the distributor and hospital pharmacy level. A drug does not have to be in an official national shortage to cause real headaches for a facility that can't get their order filled.

Who Needs to Find Adenosine — and Where Do They Get It?

Unlike oral medications that patients pick up at retail pharmacies, adenosine injection is purchased and stocked by healthcare facilities — hospitals, emergency departments, outpatient cardiac catheterization labs, cardiology offices running nuclear stress tests, and EMS systems. It is not typically dispensed by retail pharmacies. Supply chains go through hospital group purchasing organizations (GPOs) and medical distributors like Cardinal Health, McKesson, and AmerisourceBergen.

When a facility cannot source adenosine through its primary GPO contract, the search begins: calling secondary wholesalers, checking alternate NDC numbers (there are multiple generics on the market), and in some cases working with a compounding pharmacy for non-emergency uses like stress testing.

What Can Clinical Teams Do When Adenocard Is Hard to Find?

There are several practical steps hospital pharmacists and clinical teams can take:

1. Check alternate NDCs. Multiple manufacturers produce generic adenosine injection. If your primary source is out of one NDC, another may be available.
2. Call secondary and spot-market distributors. Secondary wholesalers often carry inventory that primary GPO sources are out of, though prices may be higher.
3. Prepare a backup protocol. Work with your pharmacy and cardiology team to establish a protocol for IV verapamil or IV diltiazem as second-line PSVT treatment when adenosine is unavailable.
4. Monitor the FDA shortage database. Bookmark the FDA Drug Shortage Database and check it regularly when supply seems tight.
5. Use medfinder for medication sourcing. medfinder helps locate medications at pharmacies and distributors near you. If your facility is running low on adenosine, visit

Is Adenocard the Same as Generic Adenosine?

Yes. Adenocard is the original brand name for adenosine injection manufactured by Pfizer. Generic adenosine injection (3 mg/mL) is available from multiple manufacturers and is therapeutically equivalent. Most hospitals use the generic. The key specification to verify when sourcing a generic alternative is the concentration (3 mg/mL) and the vial size — 2 mL vials (6 mg) are most common for PSVT, while 20 mL vials are used for stress testing (Adenoscan).

What Alternatives Exist If Adenosine Cannot Be Found?

For PSVT management when adenosine is unavailable, two calcium channel blockers have evidence supporting their use: IV verapamil and IV diltiazem. Both work by blocking the AV node, similar to adenosine, but with a much longer half-life (3–6 hours), meaning effects — both therapeutic and adverse — last longer. See our full guide to Adenocard alternatives for a detailed comparison.

For nuclear stress testing, regadenoson (Lexiscan) is a selective A2A adenosine receptor agonist approved as an alternative pharmacologic stress agent when adenosine is not available or is contraindicated.

The Bottom Line

Adenocard availability can fluctuate even without a formal national shortage. Understanding why supply disruptions happen — and having a plan before they do — is essential for any facility that depends on adenosine for emergency cardiac care. When you need to locate adenosine injection or any other medication, medfinder can help you find which pharmacies and distributors have it in stock near you.